News Jul 31, 2025
Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology
Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes
News Jul 31, 2025
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
News Jul 31, 2025
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
Overcoming the challenge of efficient synthesis of PKMYT1 inhibitor Lunresertib
News Jul 30, 2025
Porton Provides Support for Mednovo's RDC Drug IND
Recently, Porton Pharma Solutions Ltd. (Porton) was awarded the "2024-2025 Excellent Supplier Award" by Mednovo Group Co., Ltd. (Mednovo Group) in recognition of Porton’s professional support in the R&D of Radionuclide-Drug Conjugate (RDC).
NewslettersJul 08, 2025
Porton Newsletter - Q2 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
NewslettersJul 04, 2025
Porton Newsletter - June 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Jul 01, 2025
Porton Has Been Selected as a Representative Company in Frost & Sullivan's "2025 China Pharmaceutical CDMO Industry Insight Blue Book"
Recently, Frost & Sullivan released the “2025 China Pharmaceutical CDMO Industry Insight Blue Book”, a comprehensive analysis of the evolution and strategic trajectory of China’s pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector.
News Jun 20, 2025
Porton Shanghai Pudong R&D and Manufacturing Site Has Passed the EU QP Audit
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that its Shanghai Pudong R&D and Manufacturing Site has passed the EU Qualified Person (QP) audit.
News Jun 19, 2025
Porton Shanghai Fengxian Manufacturing Site Has Passed the EU QP Audit
The successful completion of the QP audit is a recognition of the quality management system of Shanghai Fengxian Manufacturing Site, demonstrating Porton's commitment to practicing high standard quality management. It marks that Shanghai Fengxian Manufacturing Site can provide CDMO services for small molecules, peptides and oligonucleotides, proteins and conjugate drugs that meet international standards to global customers.
